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between benfluorex and valve regurgitations was based on small observational
studies and retrospective estimations. We therefore designed an echocardio-
graphy-based multicenter study to compare the frequency of left heart valve
regurgitations in diabetic patients exposed to benfluorex for at least three
months and in diabetic controls never exposed to the drug.
Methods: This reader-blinded controlled study conducted in ten centres in
France included prospectively between November 2009 and September 2011
393 consecutive diabetic subjects previously exposed to benfluorex referred
by primary care physicians for echocardiography screening and 393 diabetic
controls. Using propensity scores, 303 patients and 303 controls were matched
for age, gender, body mass index, smoking, dyslipidemia, hypertension, coro-
nary artery disease, and previous use of other drugs associated with valve
lesions. The main outcome measure was the frequency of mild or greater left
heart valve regurgitations.
Findings: In the matched sample, the frequency and relative risk (OR) of
mild or greater left heart valve regurgitations were significantly increased in
benfluorex patients compared to controls: 30·0% vs. 13·5% (OR 2.96[1·94-
4·53]) for aortic and/or mitral regurgitation; 21·1% vs. 5·0% (OR 5·63[3·08-
10·3]) for aortic regurgitation, and 17·2% vs. 10·2% (OR 1·99[1·22-3·25]) for
mitral regurgitation. The frequency of moderate left heart valve regurgitations
was also increased among benfluorex patients vs. controls (7·3% vs. 0·7%; OR
13·9[3·21-60·7]. 
Interpretation: Our results indicate that use of benfluorex is associated
with significant increase in the frequency of left heart valve regurgitations.
The natural history of benfluorex-induced valve abnormalities needs further
research.
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Myotonic dystrophy (MD) is associated with a high risk of cardiac mor-
tality. Several causes are implicated, bradycardia, atrial and ventricular
arrhythmias, dilated cardiomyopathy and sudden death. Heart rate variability
evaluation (HRV) is a non invasive method used to evaluate the prognosis of
patients with heart disease. The purpose of the study was to evaluate the prog-
nostic value of HRV determination for the stratification risk and the follow-up
of patients with MD.
Methods: 156 patients, 79 men and 77 women, mean age 41±14 years, at
the inclusion, were recruited for a MD. Patients were asymptomatic at the
inclusion. The following studies were performed at the inclusion and repeated
4.5±3.5 years later in 124 of them. Recording of 24 hour Holter monitoring
and measurement of HRV in the time domain was calculated every 5 minutes
with the Elatec system; standard deviation of the mean RR intervals (SDNN)
(ms) was determined. Left ventricular ejection fraction (LVEF) was evaluated
at the same time by 2D echocardiography.
Results: LVEF decreased significantly from 62±8 to 58±11% (p< 0.03).
None of them had sustained ventricular tachycardia. 19 patients died (12%)
during the follow-up generally from cardiac and respiratory failure. Mean
values of SDNN did not change significantly between first inclusion
(126±42.5 ms) and last study (126±47 ms). At inclusion, SDNN was signifi-
cantly shorter in patients who died than in alive patients (109±50 msec vs
128±41) (p <0.025). Among the patients who died, initial SDNN was missing
in 6 patients, less than 100 msec in 10 patients and more than 100 msec in
only 3 patients. Among total population only 40 patients had an initial SDNN
<100 msec and 10 died (25%). Remaining patients had a SDNN >100 msec
and only 3 patients died (3%)(p< 0.0001).
Conclusions: The modifications of HRV during the follow-up were not
useful for the prediction of the occurrence of dilated cardiomyopathy or of
life-threatening arrhythmias in myotonic dystrophy, although LVEF decreased
with time. However, a low HRV (< 100msec) at the first evaluation was pre-
dictive of increasing mortality from 3 to 25%.
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Objectives: Fenfluramine derivatives have been associated with significant
risk of developing cardiac valvulopathy. This prospective study evaluated
characteristics of patients hospitalized in cardiology and who have been
exposed to these drugs.
Methods: Between july 2011 and february 2012, patients admitted in the
cardiology department, University Center of Montpellier, France, were ques-
tioned about past exposition to fenfluramine derivatives. In case of positive
response, a questionnaire assessing prescribing patterns and previous medical
history was proposed and echocardiography was performed. All usual
echocardiographic parameters were analysed. We applied criteria from the
French multicenter registry for diagnosis of drug-induced valvulopathy.
Results: Ninety patients exposed to the drugs were included. Sixty-seven
percent were women (n=60). Fifty-three percent had diabete (n=47). Ninety
percent were exposed to benfluorex (n=81). Mean treatment duration was
48 months (IC95%; 36,5-60,2). Valvular regurgitations were observed in
62,2% of patients (n=51) while 19% of patients (n=15) had pulmonary hyper-
tension. Distribution of valvulopathies is summarized in table 1. Highly pro-
bable induced valvulopathies were mild to moderate in all except 3 cases.
Conclusion: In absence of definite knowledge about evolution of drug-
induced valve disease, systematic questioning concerning fenfluramine deriv-
atives use could be recommended in hospitalized patients.
Table 1 – Distribution of regurgitations
Figure – Left heart regurgitations in patients vs. controls
Patients Mitral R Aortic R
HP 16 (20,3%) 8 (10,7%) 11 (14,3%)
PI 28 (34,1%) 20 (24,4%) 13(16,0%)
UI 22 (26,8%) 15 (18,3%) 11 (13,4%)
(HP: highly probable induced regurgitations; PI: possibly induced 
regurgitations; UI: unlikely induced regurgitations; R: regurgitation)
